SUBSCRIBE: eNewsletter
Expanded role for MRI and 2 recently approved treatment options. (©Gemalbarra/Shutterstock.com)
Distinguishing between different types of childhood arthritis is not always easy.
Psoriatic arthritis is a complex, understudied condition in older people who need more effective treatments.
Two chemical messengers are the targets of several new drugs that are in clinical trials or approved for treating psoriasis and other autoimmune diseases
Inflammatory rheumatic diseases have long been associated with increased morbidity and mortality. A new study compares the prevalence of comorbidities among psoriatic arthritis, rheumatoid arthritis and psoriasis.
Up to one-third of people with active ankylosing spondylitis (AS) have some degree of bone loss due to systemic inflammation and decreased mobility, but lowering inflammation with tumor necrosis factor blockers may improve bone density.
Psoriasis and psoriatic arthritis have long been associated with cardiovascular disease and deaths, but now a large population study from Taiwan indicates the danger of cardiac arrhythmias is increased independently of traditional risk factors such as coronary disease and high blood pressure.
Here is the case of a 30-year-old man with scalp psoriasis in whom Koebner phenomenon developed at areas of developing shingles.
The news from phase 3 trials of psoriatic arthritis treatments is upbeat: certolizumab pegol (Cimzia), apremilast (Otezla), and secukinumab (Cosentyx) all continue to show positive effects.
The goal of 90% skin clearance is “reachable” for many patients with severe psoriasis with interleukin-17 (IL-17) inhibitors. A closer look here.
Intensive treatment with statins may help reduce risk of cardiovascular events in patients with inflammatory arthritis, suggests a new study.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
